Refine
Year of publication
Document Type
- Preprint (815)
- Article (680)
- Conference Proceeding (7)
- Working Paper (2)
- Part of a Book (1)
Has Fulltext
- yes (1505)
Is part of the Bibliography
- no (1505)
Keywords
- Heavy Ion Experiments (22)
- Hadron-Hadron Scattering (14)
- Hadron-Hadron scattering (experiments) (12)
- LHC (10)
- Heavy-ion collision (6)
- Heavy-ion collisions (6)
- Jets (6)
- Heavy Quark Production (5)
- SARS-CoV-2 (5)
- ALICE experiment (4)
- COVID19-NMR (4)
- Collective Flow (4)
- Heavy Ions (4)
- Quark-Gluon Plasma (4)
- Solution NMR spectroscopy (4)
- 5′-UTR (3)
- ALICE (3)
- Diffraction (3)
- Elastic scattering (3)
- Jets and Jet Substructure (3)
- Quarkonium (3)
- meningioma (3)
- neurodegeneration (3)
- pp collisions (3)
- Beam Energy Scan (2)
- Beauty production (2)
- COVID-19 (2)
- Cancer genomics (2)
- Charm physics (2)
- Chiral Magnetic Effect (2)
- Clinical Trials and Observations (2)
- Collectivity (2)
- Correlation (2)
- Elliptic flow (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Heavy-Ion Collision (2)
- Lepton-Nucleon Scattering (experiments) (2)
- NR4A2 (2)
- PPARγ (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Polarization (2)
- Pulmonary embolism (2)
- QCD (2)
- Quark Gluon Plasma (2)
- RHIC (2)
- Relativistic heavy-ion collisions (2)
- SFAP (2)
- STAR (2)
- Shear viscosity (2)
- Single electrons (2)
- UAV (2)
- clinically important restrictions and symptoms (2)
- drug discovery (2)
- epilepsy (2)
- fragment screening (2)
- guidelines (2)
- hematopoietic stem cell transplantation (2)
- nuclear receptor (2)
- observational study (2)
- polypharmacology (2)
- rare disease (2)
- soil erosion (2)
- structural biology (2)
- transcription factor (2)
- 140Ce (1)
- 5'-UTR (1)
- 5_SL4 (1)
- 900 GeV (1)
- ABC transporters (1)
- ALICE detector (1)
- ARDS (1)
- ATAD2 (1)
- ATPases (1)
- Advanced biliary tract cancer (1)
- Alzheimer’s disease (1)
- Analysis and statistical methods (1)
- Anti-nuclei (1)
- Antibiotic Resistance (1)
- Antibiotics (1)
- Atherosclerosis (1)
- B-slope (1)
- BET inhibitors (1)
- BRD2 (1)
- BRD4 (1)
- BROMO-10 (1)
- BTC (1)
- Bacillus (1)
- Bacterial pathogens (1)
- Baryonic resonances (1)
- Beam energy scan (1)
- Biochemistry and chemical biology (1)
- Biodiversity (1)
- Biogeography (1)
- Bipolar disorder (1)
- Boosted Jets (1)
- Brain metastasis (1)
- CD74 (1)
- COVID (1)
- Calorimeters (1)
- Cancer (1)
- Cancer genetics (1)
- Canonical suppression (1)
- Cardiomyocyte signaling pathways (1)
- Cardioprotection (1)
- Cardiovascular disease (1)
- Cardiovascular diseases (1)
- Carrier-bound fibrin sealant (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Charged-particle density (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Charmonia (1)
- Chemical tools (1)
- Chiral magnetic effect (1)
- Circadian (1)
- Circulating MiRNA (1)
- Coalescence (1)
- Cold nuclear matter effects (1)
- Collagen hemostat (1)
- Collective Flow, (1)
- Comorbidities (1)
- Comparison with QCD (1)
- Conformational trapping (1)
- Coronary heart disease (1)
- Covid19-nmr (1)
- Critical care (1)
- Critical point (1)
- DIPSHIFT (1)
- Data management (1)
- Data processing methods (1)
- Data sharing (1)
- Deuteron production (1)
- Di-hadron correlations (1)
- Diagnostic markers (1)
- Direct oral anticoagulation (1)
- Disease Activity (1)
- Drug safety (1)
- Drug screening (1)
- Drug targeting (1)
- E. colo (1)
- Early Rheumatoid Arthritis (1)
- Ecology (1)
- Ecophysiology (1)
- Ecosystems (1)
- Electromagnetic transitions (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Endothelial permeability (1)
- Entomology (1)
- Environment (1)
- Experimental models of disease (1)
- Extracellular RNA (eRNA) (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Flow (1)
- Forschung (1)
- Forward physics (1)
- Freezeout (1)
- G protein-coupled receptor (GPCR) (1)
- G protein-coupled receptors (1)
- GVHD (1)
- Genomic instability (1)
- Germany (1)
- Glioblastoma survival (1)
- Groomed jet radius (1)
- HBT (1)
- HLA class II (1)
- HLA peptidome (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hand-foot syndrome (1)
- Hard Scattering (1)
- Head and neck cancer (1)
- Health risk analysis (1)
- Heart regeneration (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion (1)
- Heavy-ion detectors (1)
- Heavy-ion reactions (1)
- Hemostatics (1)
- HepG2 (1)
- Hif1α (1)
- High-throughput screening (1)
- Higher moments (1)
- HoLEP (1)
- Holmium laser enucleation (1)
- In vitro selection (1)
- Incidental prostate cancer (1)
- Inclusive spectra (1)
- Induced pluripotent stem cells (1)
- Intensity interferometry (1)
- Interference fragmentation function (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Ischemia–reperfusion injury (1)
- Italy (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- KCGS (1)
- KPS (1)
- LanI Protein (1)
- Lantibiotic (1)
- Lantibiotic Immunity (1)
- Large detector systems for particle and astroparticle physics (1)
- Lehre (1)
- Lipid metabolism (1)
- Lipoprotein (1)
- Liver Fibrosis (1)
- Liver resection (1)
- Low-molecular-weight heparin (1)
- Lymphocytes (1)
- Lymphoid Neoplasia (1)
- Lymphoid tissues (1)
- MACS (1)
- MODY (1)
- Malignant meningioma (1)
- Marine chemistry (1)
- Material budget (1)
- Medicinal chemistry (1)
- Membrane protein (1)
- Meningioma (1)
- Metabolic syndrome (1)
- MiR-29 (1)
- MicroRNAs (miRNAs) (1)
- Microbiome (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Mitochondria (1)
- Models & methods for nuclear reactions (1)
- Molecular medicine (1)
- Molecular modelling (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multiple parton interactions (1)
- Myeloid Neoplasia (1)
- Myocardial infarction (1)
- N-acetylcysteine (1)
- NK cell (1)
- NK cell subset (1)
- NMR (1)
- NMR spectroscopy (1)
- NR4A3 (1)
- Nanobody (1)
- Neolithic (1)
- Neural network (1)
- Neuropilin (1)
- Neutron physics (1)
- Next-generation sequencing (1)
- Nonflow (1)
- Nuclear Magnetic Resonance (1)
- Nuclear modification factor (1)
- Nuclear reactions (1)
- ORL (1)
- Observation (1)
- Oncology (1)
- Orphan nuclear receptor (1)
- Otorhinolaryngology (1)
- Outcome (1)
- Outcomes research (1)
- PCV (1)
- PDGFRβ (1)
- PYTHIA (1)
- Palaeoceanography (1)
- Palaeoclimate (1)
- Parkinson’s disease (1)
- Particle and Resonance Production (1)
- Particle production (1)
- Patterns of care (1)
- Pb–Pb (1)
- Performance of High Energy Physics Detectors (1)
- Periodontitis (1)
- Phage display (1)
- Phylogenomics (1)
- Population genetics (1)
- Preclinical research (1)
- Predictive markers (1)
- Production Cross Section (1)
- Prognostic markers (1)
- Prognostic models (1)
- Properties of Hadrons (1)
- Prostate cancer (1)
- Protein Structure (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Psychiatry (1)
- Pyogenic spondylodiscitis (1)
- QGP (1)
- Quark Deconfinement (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quark–gluon plasma (1)
- RNA (1)
- RNA genome (1)
- RNASolution-state NMR (1)
- RXRα (1)
- Radiative capture (1)
- Radiotherapy (1)
- Randomized controlled trial (1)
- Rapidity Range (1)
- Relativistic heavy ion physics (1)
- Remote ischemic conditioning (1)
- Research (1)
- Residency (1)
- Resolution Parameter (1)
- Resonance reactions (1)
- Resonances (1)
- Rheumatoid Arthritis (1)
- Ribosome display (1)
- Risk factor (1)
- Routine Medical Care (1)
- Rpo4/7 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SCT (1)
- SKALE score (1)
- SL1 (1)
- SL5a (1)
- SL5b (1)
- SL5b + c (1)
- SL5c (1)
- STAMPE2 (1)
- Salivary gland carcinoma (1)
- Seasonal variation (1)
- Shannon index (1)
- Single muons (1)
- Socio-ecology (1)
- SoftDrop (1)
- Solar insolation (1)
- Sorafenib (1)
- SpaI (1)
- Specialist training (1)
- Spin alignment (1)
- Splitting function (1)
- Ste2p (1)
- Strangeness enhancement (1)
- Stroke (1)
- Structural biology and molecular biophysics (1)
- Subtilin (1)
- Suicide (1)
- Sunlight (1)
- Surgery (1)
- Sweden (1)
- Systematic Uncertainty (1)
- TIRADS (1)
- TR (1)
- TTW nodules (1)
- TUR-P (1)
- Target identification (1)
- Target validation (1)
- Taxonomy (1)
- Teaching (1)
- Teeth (1)
- Therapeutic anticoagulation (1)
- Thermal model (1)
- Thrombosis (1)
- Time Projection Chamber (1)
- Tools and ressources (1)
- Topology (1)
- Tracking (1)
- Transition radiation detector (1)
- Translational research (1)
- Transurethral resection of the prostate (1)
- Transverse momentum (1)
- Transversity (1)
- Treatment (1)
- Trigger (1)
- Tumor infiltrating lymphocytes (1)
- Unemployment (1)
- University hospitals (1)
- Universitätskliniken (1)
- VEGF (1)
- VEGF receptors (1)
- VEGFR-2 (1)
- VEGFR-3 (1)
- Vector Boson Production (1)
- Wealth Losses (1)
- Weiterbildung (1)
- Wide rapidity coverage (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- Zuckerkandl’s tubercle (1)
- accident (1)
- alleles (1)
- allostery (1)
- anaemia (1)
- androgen receptor (1)
- antibodies (1)
- anticonvulsants (1)
- autism spectrum disorder (1)
- autistic disorder (1)
- azacitidine (1)
- b-cell lymphomas (1)
- bendamustine (1)
- biogeographic legaciese (1)
- biomarker (1)
- bromodomain (1)
- bromodomain inhibitor (1)
- c-kit (1)
- capture (1)
- carbon and proton assignments (1)
- cardiocerebral resuscitation (1)
- cardiopulmonary resuscitation (1)
- castration-resistant prostate cancer (1)
- cell-free expression (1)
- cerium (1)
- charge transfer (1)
- chemogenomic set (1)
- chemotherapy (1)
- chemotherapy regimen (1)
- child (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- chromatin (1)
- cirrhosis (1)
- clinical practice (1)
- cofactor recruitment (1)
- computational chemistry (1)
- copy number polymorphism (1)
- coronavirus (1)
- cross-section (1)
- cryo-EM (1)
- cytotoxicity (1)
- dE/dx (1)
- detector (1)
- dexamethasone (1)
- differential scanning fluorimetry (1)
- diffuse low-grade glioma (1)
- diffusion-weighted magnetic resonance imaging (1)
- domestication (1)
- double access (1)
- drug target (1)
- druggable genome (1)
- dynamics (1)
- ectosomes (1)
- elderly (1)
- epigenetic (1)
- everolimus (1)
- evolution (1)
- exercise (1)
- exosomes (1)
- experimental results (1)
- experiments (1)
- extracellular vesicles (1)
- fluorescence (1)
- follow-up (1)
- forest classification (1)
- forest functional similarity (1)
- fragment-based design (1)
- fragment-based drug design (1)
- freshwater ecosystems (1)
- gastric cancer (1)
- gastrointestinal stromal tumours (1)
- gene flow (1)
- genes (1)
- genetics (1)
- genome (1)
- genotype (1)
- genotype determination (1)
- glioblastoma (1)
- glioblastoma survival (1)
- glioma microenvironment (1)
- global change (1)
- habitat destruction (1)
- health (1)
- health-related quality of life (1)
- health-relatedquality of life (1)
- heavy ion experiments (1)
- heavy-ion collisions (1)
- hepatocyte nuclear factor 4α (1)
- hepatocyte transplantation (1)
- heterodimer (1)
- homodimer (1)
- homogeneous time-resolved FRET (HTRF) (1)
- hotspot loci (1)
- hypoxia (1)
- immune infiltration (1)
- immune reconstitution (1)
- injury (1)
- insect abundance (1)
- juvenile myelomonocytic leukemia (1)
- kinase inhibitor (1)
- land use (1)
- land-use change (1)
- leukapheresis (1)
- leukemia (1)
- lockdown (1)
- long-term research (1)
- lymphoma (1)
- magic angle spinning (1)
- membrane protein (1)
- membrane proteins (1)
- metabolic syndrome (1)
- metastatic renal cell carcinoma (1)
- miRNA (1)
- microdeletions (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- molecular machines (1)
- monitoring (1)
- montelukast (1)
- multiple sclerosis (1)
- multiplexed immunofluorescence (1)
- multiscale (1)
- multitarget drugs (1)
- mutation (1)
- n_TOF (1)
- neoadjuvant chemoradiotherapy (1)
- neurodevelopmental (1)
- neutron (1)
- nuclear magnetic resonance (NMR) (1)
- nuclear receptor related-1 (1)
- nuclear receptor-related 1 (1)
- nucleosynthesis (1)
- object-based classification (1)
- oral cavity cancer (1)
- p+p collisions (1)
- pediatric intensive care (1)
- peritumoral edema (1)
- peritumoral edema zone (1)
- pharmacokinetics (1)
- pharmacophore model (1)
- phase IV (1)
- phenotype (1)
- phenotypic screening (1)
- photochemistry (1)
- photogrammetry (1)
- photolabile protecting groups (1)
- phylogenetic community distance (1)
- phylogeny (1)
- pole concept of goiter growth (1)
- portal hypertension (1)
- posterior horn (1)
- posteroinferior horn (1)
- pranlukast (1)
- predictive biomarker (1)
- primary active transporters (1)
- protein folding (1)
- protein kinase (1)
- pulmonary embolism (1)
- quark gluon plasma (1)
- recurrence pattern (1)
- red blood cells (1)
- remote sensing (1)
- renin-angiotensin system (1)
- reproducibility (1)
- retinoid X receptor (1)
- rigor (1)
- risk of malignancy (1)
- rituximab (1)
- s-process (1)
- sarcoma (1)
- second-line (1)
- secondary chemical shifts (1)
- seizures (1)
- sequence alignment (1)
- signature (1)
- single nucleotide polymorphism (1)
- small molecules (1)
- solid-state NMR (1)
- soluble epoxide hydrolase (1)
- spectra (1)
- speech reports (1)
- ssFLYA (1)
- standardization (1)
- stearic acid (1)
- taller-than-wide (1)
- temozolomide (1)
- tense (1)
- therapeutic anticoagulation (1)
- threats (1)
- transfusion (1)
- trauma (1)
- tropical forests (1)
- type 2 diabetes (1)
- tyrosine kinase inhibitors (1)
- understudied kinase (1)
- zafirlukast (1)
- Υ suppression (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1274)
- Frankfurt Institute for Advanced Studies (FIAS) (1144)
- Informatik (1003)
- Medizin (74)
- Biochemie, Chemie und Pharmazie (16)
- Biochemie und Chemie (9)
- Biowissenschaften (9)
- Geowissenschaften (8)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (7)
- Pharmazie (5)
Although autism spectrum disorders (ASDs) have a substantial genetic basis, most of the known genetic risk has been traced to rare variants, principally copy number variants (CNVs). To identify common risk variation, the Autism Genome Project (AGP) Consortium genotyped 1558 rigorously defined ASD families for 1 million single-nucleotide polymorphisms (SNPs) and analyzed these SNP genotypes for association with ASD. In one of four primary association analyses, the association signal for marker rs4141463, located within MACROD2, crossed the genome-wide association significance threshold of P < 5 × 10−8. When a smaller replication sample was analyzed, the risk allele at rs4141463 was again over-transmitted; yet, consistent with the winner's curse, its effect size in the replication sample was much smaller; and, for the combined samples, the association signal barely fell below the P < 5 × 10−8 threshold. Exploratory analyses of phenotypic subtypes yielded no significant associations after correction for multiple testing. They did, however, yield strong signals within several genes, KIAA0564, PLD5, POU6F2, ST8SIA2 and TAF1C.
The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.
Cysteinyl leukotriene receptor 1 antagonists (CysLT1RA) are frequently used as add-on medication for the treatment of asthma. Recently, these compounds have shown protective effects in cardiovascular diseases. This prompted us to investigate their influence on soluble epoxide hydrolase (sEH) and peroxisome proliferator activated receptor (PPAR) activities, two targets known to play an important role in CVD and the metabolic syndrome. Montelukast, pranlukast and zafirlukast inhibited human sEH with IC50 values of 1.9, 14.1, and 0.8 μM, respectively. In contrast, only montelukast and zafirlukast activated PPARγ in the reporter gene assay with EC50 values of 1.17 μM (21.9% max. activation) and 2.49 μM (148% max. activation), respectively. PPARα and δ were not affected by any of the compounds. The activation of PPARγ was further investigated in 3T3-L1 adipocytes. Analysis of lipid accumulation, mRNA and protein expression of target genes as well as PPARγ phosphorylation revealed that montelukast was not able to induce adipocyte differentiation. In contrast, zafirlukast triggered moderate lipid accumulation compared to rosiglitazone and upregulated PPARγ target genes. In addition, we found that montelukast and zafirlukast display antagonistic activities concerning recruitment of the PPARγ cofactor CBP upon ligand binding suggesting that both compounds act as PPARγ modulators. In addition, zafirlukast impaired the TNFα triggered phosphorylation of PPARγ2 on serine 273. Thus, zafirlukast is a novel dual sEH/PPARγ modulator representing an excellent starting point for the further development of this compound class.
Introduction: Clinically complex patients often require multiple medications. Polypharmacy is associated with inappropriate prescriptions, which may lead to negative outcomes. Few effective tools are available to help physicians optimise patient medication. This study assesses whether an electronic medication management support system (eMMa) reduces hospitalisation and mortality and improves prescription quality/safety in patients with polypharmacy. Methods and analysis: Planned design: pragmatic, parallel cluster-randomised controlled trial; general practices as randomisation unit; patients as analysis unit. As practice recruitment was poor, we included additional data to our primary endpoint analysis for practices and quarters from October 2017 to March 2021. Since randomisation was performed in waves, final study design corresponds to a stepped-wedge design with open cohort and step-length of one quarter. Scope: general practices, Westphalia-Lippe (Germany), caring for BARMER health fund-covered patients. Population: patients (≥18 years) with polypharmacy (≥5 prescriptions). Sample size: initially, 32 patients from each of 539 practices were required for each study arm (17 200 patients/arm), but only 688 practices were randomised after 2 years of recruitment. Design change ensures that 80% power is nonetheless achieved. Intervention: complex intervention eMMa. Follow-up: at least five quarters/cluster (practice). recruitment: practices recruited/randomised at different times; after follow-up, control group practices may access eMMa. Outcomes: primary endpoint is all-cause mortality and hospitalisation; secondary endpoints are number of potentially inappropriate medications, cause-specific hospitalisation preceded by high-risk prescribing and medication underuse. Statistical analysis: primary and secondary outcomes are measured quarterly at patient level. A generalised linear mixed-effect model and repeated patient measurements are used to consider patient clusters within practices. Time and intervention group are considered fixed factors; variation between practices and patients is fitted as random effects. Intention-to-treat principle is used to analyse primary and key secondary endpoints.
We developed three bathochromic, green-light activatable, photolabile protecting groups based on a nitrodibenzofuran (NDBF) core with D-π-A push–pull structures. Variation of donor substituents (D) at the favored ring position enabled us to observe their impact on the photolysis quantum yields. Comparing our new azetidinyl-NDBF (Az-NDBF) photolabile protecting group with our earlier published DMA-NDBF, we obtained insight into its excitation-specific photochemistry. While the “two-photon-only” cage DMA-NDBF was inert against one-photon excitation (1PE) in the visible spectral range, we were able to efficiently release glutamic acid from azetidinyl-NDBF with irradiation at 420 and 530 nm. Thus, a minimal change (a cyclization adding only one carbon atom) resulted in a drastically changed photochemical behavior, which enables photolysis in the green part of the spectrum.
Rare copy-number variation (CNV) is an important source of risk for autism spectrum disorders (ASDs). We analyzed 2,446 ASD-affected families and confirmed an excess of genic deletions and duplications in affected versus control groups (1.41-fold, p = 1.0 × 10(-5)) and an increase in affected subjects carrying exonic pathogenic CNVs overlapping known loci associated with dominant or X-linked ASD and intellectual disability (odds ratio = 12.62, p = 2.7 × 10(-15), ∼3% of ASD subjects). Pathogenic CNVs, often showing variable expressivity, included rare de novo and inherited events at 36 loci, implicating ASD-associated genes (CHD2, HDAC4, and GDI1) previously linked to other neurodevelopmental disorders, as well as other genes such as SETD5, MIR137, and HDAC9. Consistent with hypothesized gender-specific modulators, females with ASD were more likely to have highly penetrant CNVs (p = 0.017) and were also overrepresented among subjects with fragile X syndrome protein targets (p = 0.02). Genes affected by de novo CNVs and/or loss-of-function single-nucleotide variants converged on networks related to neuronal signaling and development, synapse function, and chromatin regulation.
Background: Microdeletions are known to confer risk to epilepsy, particularly at genomic rearrangement ‘hotspot’ loci. However, microdeletion burden not overlapping these regions or within different epilepsy subtypes has not been ascertained.
Objective: To decipher the role of microdeletions outside hotspots loci and risk assessment by epilepsy subtype.
Methods: We assessed the burden, frequency and genomic content of rare, large microdeletions found in a previously published cohort of 1366 patients with genetic generalised epilepsy (GGE) in addition to two sets of additional unpublished genome-wide microdeletions found in 281 patients with rolandic epilepsy (RE) and 807 patients with adult focal epilepsy (AFE), totalling 2454 cases. Microdeletions were assessed in a combined and subtype-specific approaches against 6746 controls.
Results: When hotspots are considered, we detected an enrichment of microdeletions in the combined epilepsy analysis (adjusted p=1.06×10−6,OR 1.89, 95% CI 1.51 to 2.35). Epilepsy subtype-specific analyses showed that hotspot microdeletions in the GGE subgroup contribute most of the overall signal (adjusted p=9.79×10−12, OR 7.45, 95% CI 4.20–13.5). Outside hotspots , microdeletions were enriched in the GGE cohort for neurodevelopmental genes (adjusted p=9.13×10−3,OR 2.85, 95% CI 1.62–4.94). No additional signal was observed for RE and AFE. Still, gene-content analysis identified known (NRXN1, RBFOX1 and PCDH7) and novel (LOC102723362) candidate genes across epilepsy subtypes that were not deleted in controls.
Conclusions: Our results show a heterogeneous effect of recurrent and non-recurrent microdeletions as part of the genetic architecture of GGE and a minor contribution in the aetiology of RE and AFE.
Microangiopathy with subsequent organ damage represents a major complication in several diseases. The mechanisms leading to microvascular occlusion include von Willebrand factor (VWF), notably the formation of ultra-large von Willebrand factor fibers (ULVWFs) and platelet aggregation. To date, the contribution of erythrocytes to vascular occlusion is incompletely clarified. We investigated the platelet-independent interaction between stressed erythrocytes and ULVWFs and its consequences for microcirculation and organ function under dynamic conditions. In response to shear stress, erythrocytes interacted strongly with VWF to initiate the formation of ULVWF/erythrocyte aggregates via the binding of Annexin V to the VWF A1 domain. VWF-erythrocyte adhesion was attenuated by heparin and the VWF-specific protease ADAMTS13. In an in vivo model of renal ischemia/reperfusion injury, erythrocytes adhered to capillaries of wild-type but not VWF-deficient mice and later resulted in less renal damage. In vivo imaging in mice confirmed the adhesion of stressed erythrocytes to the vessel wall. Moreover, enhanced eryptosis rates and increased VWF binding were detected in blood samples from patients with chronic renal failure. Our study demonstrates that stressed erythrocytes have a pronounced binding affinity to ULVWFs. The discovered mechanisms suggest that erythrocytes are essential for the pathogenesis of microangiopathies and renal damage by actively binding to ULVWFs.
Sarcomas are rare cancers with high heterogeneity in terms of type, location, and treatment. The health-related quality of life (HRQoL) of sarcoma patients has rarely been investigated and is the subject of this analysis. Adult sarcoma patients and survivors were assessed between September 2017 and February 2019 in 39 study centers in Germany using standardized, validated questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)). Associated factors were analyzed exploratively using multivariable linear regressions. Among 1113 patients, clinically important limitations and symptoms were most pronounced in emotional (63%, 95% CI 60–66%), physical (60%, 95% CI 57–62%), role functioning (51%, 95% CI 48–54%), and pain (56%, 95% CI 53–59%) and fatigue (51%, 95% CI 48–54%). HRQoL differed between tumor locations with lower extremities performing the worst and sarcoma types with bone sarcoma types being most affected. Additionally, female gender, higher age, lower socioeconomic status, recurrent disease, not being in retirement, comorbidities, and being in treatment were associated with lower HRQoL. Sarcoma patients are severely restricted in their HRQoL, especially in functioning scales. The heterogeneity of sarcomas with regard to type and location is reflected in HRQoL outcomes. During treatment and follow-up, close attention has to be paid to the reintegration of the patients into daily life as well as to their physical abilities and emotional distress.
Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events. To date, only limited data on anticoagulation management after pulmonary embolism (PE) in GBM is available and the sporadic use of DOACs remains off-label. A retrospective cohort analysis of patients with GBM and postoperative, thoracic CT scan confirmed PE was performed. Clinical course, follow-up at 6 and 12 months and the overall survival (OS) were evaluated using medical charts and neuroradiological data. Out of 584 GBM patients, 8% suffered from postoperative PE. Out of these, 30% received direct oral anticoagulants (DOACs) and 70% low-molecular-weight heparin (LMWH) for therapeutic anticoagulation. There was no significant difference in major intracranial hemorrhage (ICH), re-thrombosis, or re-embolism between the two cohorts. Although statistically non-significant, a tendency to reduced mRS at 6 and 12 months was observed in the LMWH cohort. Furthermore, patients receiving DOACs had a statistical benefit in OS. In our analysis, DOACs showed a satisfactory safety profile in terms of major ICH, re-thrombosis, and re-embolism compared to LMWH in GBM patients with postoperative PE. Prospective, randomized trials are urgent to evaluate DOACs for therapeutic anticoagulation in GBM patients with PE.
Chemotherapy and diffuse low-grade gliomas : a survey within the European Low-Grade Glioma Network
(2018)
Background: Diffuse low-grade gliomas (DLGGs) are rare and incurable tumors. Whereas maximal safe, functional-based surgical resection is the first-line treatment, the timing and choice of further treatments (chemotherapy, radiation therapy, or combined treatments) remain controversial.
Methods: An online survey on the management of DLGG patients was sent to 28 expert centers from the European Low-Grade Glioma Network (ELGGN) in May 2015. It contained 40 specific questions addressing the modalities of use of chemotherapy in these patients.
Results: The survey demonstrated a significant heterogeneity in practice regarding the initial management of DLGG patients and the use of chemotherapy. Interestingly, radiation therapy combined with the procarbazine, CCNU (lomustine), and vincristine regimen has not imposed itself as the gold-standard treatment after surgery, despite the results of the Radiation Therapy Oncology Group 9802 study. Temozolomide is largely used as first-line treatment after surgical resection for high-risk DLGG patients, or at progression.
Conclusions: The heterogeneity in the management of patients with DLGG demonstrates that many questions regarding the postoperative strategy and the use of chemotherapy remain unanswered. Our survey reveals a high recruitment potential within the ELGGN for retrospective or prospective studies to generate new data regarding these issues.
Background: Glioblastoma (GBM) patients are at particularly high risk for thrombotic complications. In the event of a postoperative pulmonary embolism, therapeutic anticoagulation (tAC) is indispensable. The impact of therapeutic anticoagulation on recurrence pattern in GBM is currently unknown. Methods: We conducted a matched-pair cohort analysis of 57 GBM patients with or without tAC that were matched for age, sex, gross total resection and MGMT methylation status in a ratio of 1:2. Patients’ characteristics and clinical course were evaluated using medical charts. MRI characteristics were evaluated by two independent authors blinded to the AC status. Results: The morphologic MRI appearance in first GBM recurrence showed a significantly higher presence of multifocal, midline crossing and sharp demarcated GBM recurrence patterns in patients with therapeutic tAC compared to the matched control group. Although statistically non-significant, the therapeutic tAC cohort showed increased survival. Conclusion: Therapeutic anticoagulation induced significant morphologic changes in GBM recurrences. The underlying pathophysiology is discussed in this article but remains to be further elucidated.
Background: Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events. To date only limited data on anticoagulation management after pulmonary embolism (PE) in GBM is available and the sporadic use of DOACs remains off-label.
Methods: A retrospective cohort analysis of patients with GBM and postoperative, thoracic CT-scan confirmed, PE was performed. Clinical course, follow-up at 6 and 12 months and the overall survival (OS) were evaluated using medical charts and neuroradiological data.
Results: Out of 584 GBM patients, 8% suffered from postoperative PE. Out of theses, 30% received direct oral anticoagulants (DOACs) and 70% low-molecular-weight heparin (LMWH) for therapeutic anticoagulation. There was no significant difference in major intracranial hemorrhage (ICH), re-thrombosis or re-embolism between the two cohorts. Although statistically non-significant, a tendency to reduced mRS at 6- and 12 months was observed in the LMWH cohort. Furthermore, patients receiving DOACs had a statistical benefit in OS.
Conclusion: In our analysis DOACs showed a satisfactory safety profile in terms of major ICH, re-thrombosis and re-embolism compared to LMWH in GBM patients with postoperative PE. Prospective, randomized trials are urgent to evaluate DOACs for therapeutic anticoagulation in GBM patients with PE.
Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer
(2017)
Global changes in chromatin accessibility may drive cancer progression by reprogramming transcription factor (TF) binding. In addition, histone acetylation readers such as bromodomain-containing protein 4 (BRD4) have been shown to associate with these TFs and contribute to aggressive cancers including prostate cancer (PC). Here, we show that chromatin accessibility defines castration-resistant prostate cancer (CRPC). We show that the deregulation of androgen receptor (AR) expression is a driver of chromatin relaxation and that AR/androgen-regulated bromodomain-containing proteins (BRDs) mediate this effect. We also report that BRDs are overexpressed in CRPCs and that ATAD2 and BRD2 have prognostic value. Finally, we developed gene stratification signature (BROMO-10) for bromodomain response and PC prognostication, to inform current and future trials with drugs targeting these processes. Our findings provide a compelling rational for combination therapy targeting bromodomains in selected patients in which BRD-mediated TF binding is enhanced or modified as cancer progresses.
Nuclear receptor related 1 (Nurr1) is an orphan ligand-activated transcription factor and considered as neuroprotective transcriptional regulator with great potential as therapeutic target for neurodegenerative diseases. However, the collection of available Nurr1 modulators and mechanistic understanding of Nurr1 are limited. Here, we report the discovery of several structurally diverse non-steroidal anti-inflammatory drugs as inverse Nurr1 agonists demonstrating that Nurr1 activity can be regulated bidirectionally. As chemical tools, these ligands enable unraveling the co-regulatory network of Nurr1 and the mode of action distinguishing agonists from inverse agonists. In addition to its ability to dimerize, we observe an ability of Nurr1 to recruit several canonical nuclear receptor co-regulators in a ligand-dependent fashion. Distinct dimerization states and co-regulator interaction patterns arise as discriminating factors of Nurr1 agonists and inverse agonists. Our results contribute a valuable collection of Nurr1 modulators and relevant mechanistic insights for future Nurr1 target validation and drug discovery.
Cell-free expression represents an attractive method to produce large quantities of selectively labeled protein for NMR applications. Here, cell-free expression was used to label specific regions of the growth hormone secretagogue receptor (GHSR) with NMR-active isotopes. The GHSR is a member of the class A family of G protein-coupled receptors. A cell-free expression system was established to produce the GHSR in the precipitated form. The solubilized receptor was refolded in vitro and reconstituted into DMPC lipid membranes. Methionines, arginines, and histidines were chosen for 13C-labeling as they are representative for the transmembrane domains, the loops and flanking regions of the transmembrane α-helices, and the C-terminus of the receptor, respectively. The dynamics of the isotopically labeled residues was characterized by solid-state NMR measuring motionally averaged 1H-13C dipolar couplings, which were converted into molecular order parameters. Separated local field DIPSHIFT experiments under magic-angle spinning conditions using either varying cross polarization contact times or direct excitation provided order parameters for these residues showing that the C-terminus was the segment with the highest motional amplitude. The loop regions and helix ends as well as the transmembrane regions of the GHSR represent relatively rigid segments in the overall very flexible receptor molecule. Although no site resolution could be achieved in the experiments, the previously reported highly dynamic character of the receptor concluded from uniformly 13C labeled receptor samples could be further specified by this segmental labeling approach, leading to a more diversified understanding. of the receptor dynamics under equilibrium conditions
The Kinase Chemogenomic Set (KCGS): an open science resource for kinase vulnerability identification
(2021)
We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show potent kinase inhibition and a narrow spectrum of activity when screened across a large panel of kinase biochemical assays. Currently, the set contains 187 inhibitors that cover 215 human kinases. The kinase chemogenomic set (KCGS), current Version 1.0, is the most highly annotated set of selective kinase inhibitors available to researchers for use in cell-based screens.
Background & aims: Current guidelines recommend immunosuppressive treatment (IT) in patients with primary sclerosing cholangitis (PSC) and elevated aminotransferase levels more than five times the upper limit of normal and elevated serum IgG-levels above twice the upper limit of normal. Since there is no evidence to support this recommendation, we aimed to assess the criteria that guided clinicians in clinical practice to initiate IT in patients with previously diagnosed PSC.
Methods: This is a retrospective analysis of 196 PSC patients from seven German hepatology centers, of whom 36 patients had received IT solely for their liver disease during the course of PSC. Analyses were carried out using methods for competing risks.
Results: A simplified autoimmune hepatitis (AIH) score >5 (HR of 36, p<0.0001) and a modified histological activity index (mHAI) greater than 3/18 points (HR 3.6, p = 0.0274) were associated with the initiation of IT during the course of PSC. Of note, PSC patients who subsequently received IT differed already at the time of PSC diagnosis from those patients, who did not receive IT during follow-up: they presented with increased levels of IgG (p = 0.004) and more frequently had clinical signs of cirrhosis (p = 0.0002).
Conclusions: This is the first study which investigates the parameters associated with IT in patients with PSC in clinical practice. A simplified AIH score >5 and a mHAI score >3, suggesting concomitant features of AIH, influenced the decision to introduce IT during the course of PSC. In German clinical practice, the cutoffs used to guide IT may be lower than recommended by current guidelines.
Background Microdeletions are known to confer risk to epilepsy, particularly at genomic rearrangement “hotspot” loci. However, deciphering their role outside hotspots and risk assessment by epilepsy sub-type has not been conducted.
Methods We assessed the burden, frequency and genomic content of rare, large microdeletions found in a previously published cohort of 1,366 patients with Genetic Generalized Epilepsy (GGE) plus two sets of additional unpublished genome-wide microdeletions found in 281 Rolandic Epilepsy (RE) and 807 Adult Focal Epilepsy (AFE) patients, totaling 2,454 cases. These microdeletion sets were assessed in a combined analysis and in sub-type specific approaches against 6,746 ethnically matched controls.
Results When hotspots are considered, we detected an enrichment of microdeletions in the combined epilepsy analysis (adjusted-P= 2.00×10-7; OR = 1.89; 95%-CI: 1.51-2.35), where the implicated microdeletions overlapped with rarely deleted genes and those involved in neurodevelopmental processes. Sub-type specific analyses showed that hotspot deletions in the GGE subgroup contribute most of the signal (adjusted-P = 1.22×10-12; OR = 7.45; 95%-CI = 4.20-11.97). Outside hotspot loci, microdeletions were enriched in the GGE cohort for neurodevelopmental genes (adjusted-P = 4.78×10-3; OR = 2.30; 95%-CI = 1.42-3.70), whereas no additional signal was observed for RE and AFE. Still, gene content analysis was able to identify known (NRXN1, RBFOX1 and PCDH7) and novel (LOC102723362) candidate genes affected in more than one epilepsy sub-type but not in controls.
Conclusions Our results show a heterogeneous effect of recurrent and non-recurrent microdeletions as part of the genetic architecture of GGE and a minor to negligible contribution in the etiology of RE and AFE.
Protein kinases are highly tractable targets for drug discovery. However, the biological function and therapeutic potential of the majority of the 500+ human protein kinases remains unknown. We have developed physical and virtual collections of small molecule inhibitors, which we call chemogenomic sets, that are designed to inhibit the catalytic function of almost half the human protein kinases. In this manuscript we share our progress towards generation of a comprehensive kinase chemogenomic set (KCGS), release kinome profiling data of a large inhibitor set (Published Kinase Inhibitor Set 2 (PKIS2)), and outline a process through which the community can openly collaborate to create a KCGS that probes the full complement of human protein kinases.